Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Saturday, October 01, 2016
 Services
Submit a manuscript
Subscribe
Individuals
Institutions
Response
Send response
Read responses
Reprint
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
Readers
Authors
Reviewers
Advertisers
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2009; 7(12): 1174-1180
DOI: 10.3736/jcim20091216
Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines
1. Ying DENG (Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China )
2. Hong-feng CHEN (Department of Breast Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China E-mail: chhfluk@yahoo.com.cn)
Objective: To observe the effects of Astragalus injection, astragaloside Ⅳ and formononetin on proliferation and Akt phosphorylation of basal-like human breast carcinoma cell lines MDA-MB-468 and MDA-MB-231.
Methods: The effects of different concentrations of Astragalus injection, astragaloside Ⅳ and formononetin on proliferation of breast cancer cell lines were assayed by methyl thiazolyl tetrazolium (MTT) assay, and their effects on phospho-Akt were assayed by in-cell Western blot method.
Results: The results of the MTT assay showed that the best concentrations of Astragalus injection, astragaloside Ⅳ, formononetin and astragaloside Ⅳ plus formononetin were 1 g/mL, 80 μg/mL, 40 μg/mL and 10 μg/mL plus 40 μg/mL respectively. After 1- or 2-day culture, Astragalus injection, astragaloside Ⅳ, formononetin and astragaloside Ⅳ plus formononetin decreased the expressions of p-Akt (Thr 308) and p-Akt (Ser 473) in MDA-MB-468 cells. Formononetin and astragaloside Ⅳ plus formononetin down-regulated the expression of p-Akt (Thr 308) protein in MDA-MB-231 cells after 1- and 2-day culture, but had no effects on the expression of p-Akt (Ser 473) protein in MDA-MB-231 cells.
Conclusion: Astragalus injection, astragaloside Ⅳ and formononetin can inhibit proliferation of breast cancer cell lines MDA-MB-468 and MDA-MB-231, and the antiproliferation effects vary according to their concentrations. And the antiproliferation mechanisms may be related to their down-regulation effects on Akt phosphorylation.
Welcome to JCIM! You are the number 9746 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Deng Y, Chen HF. Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2009; 7(12): 1174-1180.
References:
1Shen ZZ, Shao ZM. Breast tumor[M]. Shanghai: Shanghai Scientific and Technical Publishers, 2005. 1-2. Chinese.
2Qin HG. Professor Tang Han-Jun's thinking in syndrome differentiation and experience in treating breast cancer[J]. J Chin Integr Med, 2004, 2(4): 297-298. Chinese.
3Lu DM. Qi- and ying-tonifying method for breast cancer patients after mastectomy[J].Shanghai Zhong Yi Yao Da Xue Xue Bao, 2008, 22(1): 1-3. Chinese.
4Liu PX, Zhou RF, Tan M. Effects of Astragalus injection on proliferation and apoptosis of basal-like breast cancer cell line MDA-MB-231[J].Zhonghua Ru Xian Bing Xue Za Zhi, 2009, 3(2): 28-31. Chinese with abstract in English.
5Ye MN, Chen HF. Effects of Astragalus injection on proliferation of basal-like breast cancer cell line MDA-MB-468[J]. J Chin Integr Med, 2008, 6(4): 399-404. Chinese with abstract in English.
6Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer[J].Breast Cancer Res, 2005, 7(4): 143-148.  .
7Langerфd A, Zhao H, Borgan Ф, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Bфrresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer[J].Breast Cancer Res, 2007, 9(3): R30.  .
8Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res, 2004, 10(16): 5367-5374.  .
9Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms[J].BMC Genomics, 2006, (7): 96.  .
10van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J].Am J Pathol, 2002, 161(6): 1991-1996.  .
11Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis[J].Lab Invest, 2002, 82(11): 1525-1533.  .

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977